KRRO Korro Bio, Inc.
Company Analysis
Latest News
🔴 Korro Bio is trading 6.97% down in pre-market as global yields pressure biotech shares
Korro Bio is trading $11.62 (-6.97%) in pre-market as rising global yields pressure risk-sensitive biotechnology shares. - No new company-specific...
🟢 Korro Bio rises 5.4% — Biotech Sector Gains Amid Broad Market Rally and Positive Sentiment
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, represented by the XBI ETF, is...
🔴 Korro Bio is trading 6.25% down in after-hours trading after biotech ETFs reversed sharply
Korro Bio is trading 6.25% down at $12.15 after a broad biotech-sector pullback. - It fell 7.10% during the August 20, 2026 regular session; no...
🔴 Korro Bio falls 5.3% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
Korro Bio Submits Application to Initiate Phase 1/2 Clinical Trial for KRRO-121
Korro Bio, Inc. announced it has submitted an application to the Australian Alfred Health Human Ethics Committee to begin a first-in-human Phase 1/2 clinical...
🟢 Korro Bio rises 5.3% — Biotech Sector Surges on Positive mRNA Cancer Vaccine Trial Results
With Biotech (XBI) up 3.7%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, proxied by the XBI ETF, is trading...
Korro Bio, Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
For the second quarter of 2026, analysts expect Korro Bio to report a consensus revenue of $0.51 million and an EPS loss of $1.54, with the stock currently...
🟢 Korro Bio is trading 6.4% up today after narrower net loss
Korro Bio is trading 6.4% up now at $12.89 after August 6, 2026 earnings highlighted a narrower $18.9 million net loss. - Cash totaled $137.9 million, with...
Korro Bio narrows second quarter 2026 net loss to $18.9M and extends cash runway into the second half of 2028.
Korro Bio reported a net loss of $18.9 million, or ($1.07) per share, for the second quarter of 2026, with no collaboration revenue recognized. The company...
🟢 Korro Bio is trading 5.6% up today amid a broad biotech rally and risk-on market sentiment
Korro Bio is trading at $11.34 (+5.59%) with no company-specific news, moving higher alongside a broad risk-on session and strength in the biotech sector. •...
🔴 Korro Bio is trading 5.3% down today on normal volatility
Korro Bio is trading 5.3% down at $10.07 today on normal volatility, as there are no fresh company-specific catalysts or news releases to drive the price...
🔴 Korro Bio is trading 8.1% down today amid broad market weakness and after-hours volatility
Korro Bio is trading at $9.25 (8.1% down) in after-hours trading, extending a downward trend from recent highs amid broad market weakness. • The stock...
🟢 Korro Bio rises 5.7% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Korro Bio is trading 5.4% down today, extending a week-long slide with no clear catalyst
Korro Bio is trading 5.4% down today at $10.91, extending a week-long slide despite a lack of fresh company-specific news or regulatory filings. • The decline...
🟢 Korro Bio is trading 5% up today on a technical rebound from recent losses
Korro Bio is trading at $12.08 (up 5%) as the stock stages a relief bounce following a sharp 6.1% drop on July 20 and a week of broader declines. • The move...
🟢 Korro Bio is trading 5% up today as it rebounds from recent losses
Korro Bio is trading at $12.08 (5% up) in pre-market as it rebounds from recent losses, including a 6.1% decline on July 20, 2026. • No fresh company-specific...
🔴 Korro Bio, Inc. is trading 5.51% down
KRRO is trading at $11.57, down 5.51%.
🔴 Korro Bio is trading 5.1% down today amid a broad biotech selloff and continued fallout from failed drug data
Korro Bio is trading at $12.37 (-5.10%) as it extends a sharp selloff driven by sector-wide weakness and recent negative clinical developments. • The biotech...
🔴 Korro Bio is trading 5.3% down today as it digests failed KRRO-110 trial and paused Novo Nordisk partnership
Korro Bio is trading 5.3% down today at $12.79 as the stock continues to digest the impact of its failed KRRO-110 program and paused Novo Nordisk RNA...
🔴 Korro Bio is trading 5.2% down today amid broader biotech weakness and post-trial volatility
Korro Bio is trading at $13.80 (-5.19%) as it extends its post-trial volatility with no new company-specific catalysts identified in current coverage. • The...